Adam Kittai, MD, breaks down the evolving landscape of CLL sequencing—from venetoclax retreatment to triplet regimens. As he puts it, “We don’t have that 1, 2 study published,” speaking to results ...

Medical experts are urging a shift in how clinicians evaluate mental health, emphasizing that effective treatment for depression, anxiety, and cognitive decline must begin with sl ...

ARACOG trial data highlight cognitive effects of ARPIs in prostate cancer, showing less cognitive decline with darolutamide than enzalutamide, notes Alicia Morgans, MD, MPH. Darolutamide is associated ...

Intraoperative cesium-131 tile-based radiation therapy (TBRT) with GammaTile significantly improved local control, surgical bed recurrence-free survival (SB-RFS), and overall surv ...

While lifestyle alterations have been previously recommended to control potassium levels for some patients with hyperkalemia, ...

In HepG2.117 cells, ALG-001075 achieved HBV DNA EC50 0.64 nM, outperforming canocapavir (5.8 nM) and neracorvir (24 nM) with ...

Teclistamab (Tecvayli; Johnson & Johnson) appears poised to move into earlier lines of care as a monotherapy, as bispecific antibodies made big news in the treatment of blood cancers and disorders on ...

Fragmented subspecialty care and underbuilt survivorship pathways risk overwhelming primary care as the survivor population ...

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes ...

Fee-for-service beneficiaries had higher BGP use than Medicare Advantage (25.8% vs 24.6%; AOR 1.08), indicating payer ...

Accelerating private equity “roll-up” consolidation can evade antitrust thresholds, and post-acquisition staffing reductions have been associated with higher hospital-acquired conditions, falls, ...

Combination tobevibart 300 mg + elebsiran 200 mg q4w achieved HDV RNA TND in 77% at week 72 and 88% at week 96, outperforming tobevibart monotherapy. Profound HBsAg lowering occurred with dual therapy ...